Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk

Prostate. 2005 Aug 1;64(3):240-5. doi: 10.1002/pros.20210.

Abstract

Background: To determine longitudinal PSA changes over a period of 10 years in patients with and without prostate cancer.

Methods: Serial PSA measurements performed over 10 years were evaluated in 353 men who eventually developed prostate cancer and in 2.462 participants of a screening program without prostatic malignancy.

Results: In men with cancer, mean tPSA increased from 2.28 ng/ml at 10 years before diagnosis to 6.37 ng/ml at the time of postive biopsy (PSA velocity: 0.409 ng/ml/year). PSA velocity was significantly associated with Gleason scores and pathologic stage. In the benign group (n=2.462), mean tPSA increased from 1.18 to 1.49 ng/ml over a period of 10 years (PSA velocity of 0.03 ng/ml/year). Of the subjects with tPSA levels of 2 ng/ml or less, 2 years prior to cancer diagnosis, 11.4% had tPSA values of more than 4 ng/ml at the time of biopsy. Of the 972 men with tPSA below 1 ng/ml 2 years before the most recent measurement was obtained, 966 (99.4%) had no evidence of prostate cancer 2 years later, while six were found to have malignancies (0.6%).

Conclusions: Longitudinal PSA changes in men with and without prostate cancer are significantly different. Annual testing may not be required in men with baseline tPSA levels of 1 ng/ml or below, whereas in patients with levels higher than 1 ng/ml, it seems to be indicated because of the significant percentage of men presenting with tPSA levels of more than 4 ng/ml two years later.

MeSH terms

  • Adult
  • Aged
  • Biopsy
  • Humans
  • Longitudinal Studies
  • Male
  • Mass Screening
  • Middle Aged
  • Predictive Value of Tests
  • Prostate-Specific Antigen / blood*
  • Prostatic Hyperplasia / blood
  • Prostatic Hyperplasia / epidemiology
  • Prostatic Hyperplasia / pathology
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / epidemiology*
  • Prostatic Neoplasms / pathology
  • Reference Values
  • Risk Factors

Substances

  • Prostate-Specific Antigen